BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23143188)

  • 1. Toxicologic pathology in the 21st century.
    Ettlin RA
    Toxicol Pathol; 2013 Jul; 41(5):689-708. PubMed ID: 23143188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modern imaging technologies in toxicologic pathology: An overview.
    Ying X; Monticello TM
    Toxicol Pathol; 2006; 34(7):815-26. PubMed ID: 17178685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the toxicologic pathologist in the post-genomic era(#).
    Maronpot RR
    J Toxicol Pathol; 2013 Jun; 26(2):105-10. PubMed ID: 23914052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
    Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
    Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A brief review of modern toxicologic pathology in regulatory and explanatory toxicity studies of chemicals.
    Ettlin RA; Oberholzer M; Perentes E; Ryffel B; Kolopp M; Qureshi SR
    Arch Toxicol; 1991; 65(6):445-53. PubMed ID: 1929864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicologic pathology: looking ahead.
    Schwetz BA
    Toxicol Pathol; 2003; 31 Suppl():2-5. PubMed ID: 12597424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein biomarkers for in vitro testing of toxicology.
    Schrattenholz A; Šoškić V; Schöpf R; Poznanović S; Klemm-Manns M; Groebe K
    Mutat Res; 2012 Aug; 746(2):113-23. PubMed ID: 22405942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response letter from Clinical Pathology Interest Group of the Society of Toxicologic Pathology (STP) for manuscript entitled International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies by Bolon et al.
    Tripathi NK; Schultze AE; Pearson RC; Everds NE; Elliott GS; Ramaiah L; Wells MY; Latimer KS; Walter GL; Katavolos P; Collins ND; Tarrant J; Walker DB; Topper MJ; Jordan HL; O'Rourke LG; Guilpin VB; Brockus CW; Wilcox AL; Clemo FA; Smith GS; Reagan WJ; McCartney JE
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):39. PubMed ID: 21676604
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory forum opinion piece: the role of the toxicologic pathologist in the postgenomic era: challenges and opportunities.
    Maronpot RR
    Toxicol Pathol; 2012 Oct; 40(7):1082-6. PubMed ID: 22585943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternatives to animal experimentation in basic research.
    Gruber FP; Hartung T
    ALTEX; 2004; 21 Suppl 1():3-31. PubMed ID: 15586255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational toxicology--a state of the science mini review.
    Kavlock RJ; Ankley G; Blancato J; Breen M; Conolly R; Dix D; Houck K; Hubal E; Judson R; Rabinowitz J; Richard A; Setzer RW; Shah I; Villeneuve D; Weber E
    Toxicol Sci; 2008 May; 103(1):14-27. PubMed ID: 18065772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on past practices and future trends in toxicologic neuropathology: notes from a keynote address by Dr. Peter S. Spencer.
    Bolon B
    Toxicol Pathol; 2011 Jan; 39(1):15-8. PubMed ID: 21075919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory forum opinion piece: Tox21 and toxicologic pathology.
    Bucher JR
    Toxicol Pathol; 2013 Jan; 41(1):125-7. PubMed ID: 22692375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the toxicologic pathologist in the biopharmaceutical industry.
    van Tongeren S; Fagerland JA; Conner MW; Diegel K; Donnelly K; Grubor B; Lopez-Martinez A; Bolliger AP; Sharma A; Tannehill-Gregg S; Turner PV; Wancket LM
    Int J Toxicol; 2011 Oct; 30(5):568-82. PubMed ID: 21878555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathology and clinical medicine in the 21st Century].
    Denk H
    Verh Dtsch Ges Pathol; 2001; 85():80-6. PubMed ID: 11894418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicogenomics in biomarker discovery.
    Decristofaro MF; Daniels KK
    Methods Mol Biol; 2008; 460():185-94. PubMed ID: 18449488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The re-emergence (or the decline) of toxicologic pathology.
    Alden CL
    Toxicol Pathol; 2009 Aug; 37(5):570-1. PubMed ID: 19638439
    [No Abstract]   [Full Text] [Related]  

  • 18. A personal perspective on the past, present, and future of Toxicologic Pathology.
    Trump BF
    Toxicol Pathol; 1997; 25(4):426-8. PubMed ID: 9280134
    [No Abstract]   [Full Text] [Related]  

  • 19. From alternative methods to a new toxicology.
    Hartung T
    Eur J Pharm Biopharm; 2011 Apr; 77(3):338-49. PubMed ID: 21195172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory Forum opinion piece: image analysis-based cell proliferation studies using electronic images: the CEPA industry working group's proposal.
    Dölemeyer A; Mudry MC; Kohler M; Schorsch F
    Toxicol Pathol; 2013; 41(8):1170-3. PubMed ID: 23827979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.